Clinical trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in Norway
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 3 |
| 2008 | 1 |
| 2009 | 4 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 11 |
| Terminated | 2 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 5 |
| Princess Maxima Center for Pediatric Oncology | 4 |
| Amgen | 2 |
| Bristol-Myers Squibb | 2 |
| Charite University, Berlin, Germany | 2 |
| Mats Heyman | 2 |
| Nordic Society for Pediatric Hematology and Oncology | 2 |
| Oslo University Hospital | 2 |
| Rigshospitalet, Denmark | 2 |
| Bambino Gesù Hospital and Research Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 34 |
| Leukemia | 8 |
| Recurrence | 6 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Leukemia, Myeloid, Acute | 2 |
| Neoplasm, Residual | 2 |
| Neoplasms | 2 |
| Agnosia | 1 |
Trials
Showing 26 to 34 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.